Announcements & Press Releases

TUCSON, Ariz., March 23, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc., an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistant...

TUCSON, Ariz., March 16, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of...

TUCSON, Ariz., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug...

TUCSON, Ariz., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug...

TUCSON, Ariz., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Accelerate Diagnostics, Inc. (Nasdaq:AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX), announced today that it has completed its previously announced rights offering. Through broad participation from both insiders and non-insider...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections,...

Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections,...

Accelerate Diagnostics, Inc. (AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections,...

Accelerate Diagnostics, Inc. (AXDX), announced today that it has completed its previously announced rights offering. Through broad participation from both insiders and non-insider investors, the...

Accelerate Diagnostics, Inc. (AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections,...

Accelerate Diagnostics, Inc. (AXDX), today announced that it has appointed Pete Bantock to the position of Chief Commercial Officer, effective today. Most recently Pete was Sr. Vice President and...

Accelerate Diagnostics, Inc. (AXDX), an in vitro diagnostics company dedicated to providing solutions for the global challenge of drug resistant organisms and hospital acquired infections, today...

Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi,...

Accelerate Diagnostics Announces Plans For Rights Offering To StockholdersTUCSON, Ariz., June 4, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX), an in vitro diagnostics company dedicated...

Accelerate Diagnostics, Inc. Names Frank J. M. ten Brink to Board of DirectorsTUCSON, Ariz., March 6, 2013 /PRNewswire/ -- Accelerate Diagnostics, Inc. (AXDX), a developer of automated diagnostic...

Accelr8 Technology Corporation (NYSE MKT: AXK) announced today that its common stock has been approved by The NASDAQ Stock Market, LLC for listing on the NASDAQ Capital Market. The Company expects...

Accelr8 Closes on InvestmentDenver, Co., June 26, 2012 – Accelr8 Technology Corporation (NYSE MKT: AXK) announced today that it has received shareholder approval, met all closing conditions, and...

Denver, Co., June 22, 2012 – Accelr8 Technology Corporation (NYSE MKT: AXK) announced results of two studies that it presented at the 112th annual General Meeting of the American Society for...

Accelr8 and Denver Health Notified by Department of Defense for Rapid Diagnostics AwardDENVER, Colo., May 15, 2012 – Accelr8 Technology Corporation (NYSE MKT: AXK) and Denver Health received...

DENVER, Colo., April 23, 2012 – Accelr8 Technology Corporation (Amex: AXK) announced today that an investment group formed by Jack Schuler, John Patience, and Larry Mehren will invest a total of...

Accelr8 Announces New ManagementDenver, Co., June 26, 2012 – Accelr8 Technology Corporation (NYSE MKT: AXK) today announced the appointment of Lawrence Mehren as President and Chief Executive...

Accelr8 Announces Development Expansion for Blood-Based Diagnostic TestsDENVER, Colo., November 22, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that it successfully completed...

Accelr8 Announces Interim Plan and Advanced StudiesDENVER, Colo., October 13, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that upon reaching the end of its technology...

Accelr8 Announces Renewal and Expansion of SCHOTT Microarray License, and Notice of Allowance for New PatentDENVER, Colo., September 22, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK)...

Accelr8 Announces Results in Award-Winning Presentation for Rapid Diagnostics with ICU SpecimensCHIGACO, Ill., September 19, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced...

Accelr8 Announces Continuation and Expansion of BACcel™ Development Collaboration DENVER, Colo., July 25, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that Accelr8 and...

Accelr8 to Receive Award for ICAAC PresentationThe presentation title is "Same-Shift ID Directly from Respiratory Specimens by Automated Microscopy." It will report results from a study using Accelr8'

Accelr8 Announces Continuation of BACcel™ CollaborationDENVER, Colo., June 30, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced that the company agreed to extend its letter of...

Accelr8 4-Hour Test Identifies New Drug-Resistant "Staph" (hVISA) Undetectable by Hospital LabsDENVER, Colo., May 23, 2011 – Accelr8 Technology Corporation (NYSE Amex: AXK) announced results from...

Accelr8 Announces Initial Results from ICU Pilot Clinical Study for Same-Day, Multi-Organism, Multi-Resistance Diagnostics Presented at ATS DENVER, Colo., May 16, 2011 – Accelr8 Technology...

Accelr8 Announces Option Exercise to BACcel™ Technology Evaluation, and Additional Presentations at Major Medical Meetings DENVER, Colo., April 14, 2011 – Accelr8 Technology Corporation (NYSE...

Accelr8 Announces First European Presentation of Rapid Diagnostic Results for New Drug Resistance TestDENVER, Colo., March 1, 2011 – Accelr8 Technology Corporation (NYSE Alternext US: AXK)...

ACME Inc. (NYSE: ) today reported financial results for the fourth quarter and full year ended December 31, 2010. For the fourth quarter 2010, we...

DENVER, Colo., February 22, 2011 – Accelr8 Technology Corporation (NYSE Alternext US: AXK) announced that clinical research collaborators at the Denver Health Medical Center received...

Body copy of news release

Body copy of news release.